GLP-1 Receptor Agonist: Wegovy Access at $399/Month
Wegovy access offers a transparent $399 monthly self-pay option for FDA-approved GLP-1 receptor agonist therapy. This pricing reduces cost barriers for patients managing obesity. Clinicians can now counsel patients more effectively on affordable…
Daily Cannabis Use and Moderate-to-Severe Use Disorder Risk in Primary Care
Cannabis use disorder prevalence increases with frequency of use, especially among daily users in primary care. This study highlights a 1-in-5 chance of moderate-to-severe disorder among daily cannabis users. Understanding cannabis use disorder…
Patients Report Lower Satisfaction at Medicinal Cannabis Clinics vs General Practice
A 2025 Australian survey reveals patient satisfaction medicinal cannabis clinics is lower than in general practice settings. Patients reported less satisfaction with consultation time, information on risks and benefits, and treatment integration. These…
Eli Lilly’s Oral GLP-1 Therapy Now Sold on Amazon
Oral GLP-1 therapy is transforming weight management with Eli Lilly’s new pill available on Amazon. This direct-to-consumer approach allows patients easier access but requires careful clinical oversight. Family physicians should integrate oral GLP-1…
Avoiding the Biggest Clinical Mistakes in GLP-1 Receptor Agonist Use
GLP-1 receptor agonist clinical mistakes often reduce treatment effectiveness and safety. Patients frequently discontinue therapy prematurely or mismanage dosing. Recognizing and addressing these errors is essential for optimal weight management outcomes.
Clinical Evidence on Dietary Fiber and GLP-1 Receptor Agonists
Dietary fiber GLP-1 receptor agonist effects are emerging as a complementary approach in metabolic health. This evidence highlights the potential role of fermentable fibers in appetite regulation. Family medicine clinicians should consider dietary fiber…
GLP-1 Drugs Reshape Food Markets: Tapatío Sales Surge
GLP-1 receptor agonist benefits include appetite regulation and shifts in food preferences. Patients on these drugs often seek stronger flavors to enhance smaller meals. This trend is reflected in the surge of Tapatío hot sauce sales.
Compounded Semaglutide: Weight Management Medicine Facts
Compounded GLP-1 therapy offers an alternative approach to weight management with semaglutide. This therapy lacks FDA approval as a finished drug product, raising safety considerations. Telehealth prescribing of compounded semaglutide requires careful…
Clinical Evidence on GLP-1 Receptor Agonist Telehealth Transition
GLP-1 receptor agonist telehealth transition is reshaping patient access to therapies. The phase-out of compounded semaglutide highlights regulatory shifts toward FDA-approved medications. Clinicians must adapt to these changes to ensure continuity of…
GLP-1 Pills vs Shots: Clinical Evidence and Patient Considerations
Oral semaglutide clinical evidence highlights important differences between pills and injectable GLP-1 receptor agonists. Understanding these differences helps clinicians tailor treatments for weight management. Patient adherence and formulation choice…